Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1215368 | 1.00 | ALOX15 (0.44) | ALOX15ALDH1A1ITGB3ITGA2BITGB1 | |
| SCHEMBL1217905 | 0.97 | ALOX15 (0.43) | ALOX15ALDH1A1ITGB3ITGA2BITGB1 | |
| SCHEMBL1214921 | 0.95 | ALOX15 (0.48) | ALOX15ALDH1A1ITGB3ITGA2BITGB1 | |
| SCHEMBL1212374 | 0.94 | ALOX15 (0.47) | ALOX15ALDH1A1ITGB3ITGA2BITGB1 | |
| SCHEMBL1210954 | 0.94 | ALOX15 (0.40) | ALOX15ALDH1A1ITGB3ITGA4PPARG | |
| SCHEMBL1214662 | 0.94 | ALOX15 (0.47) | ALOX15ALDH1A1ITGB3ITGA2BITGB1 | |
| SCHEMBL1215597 | 0.94 | ALOX15 (0.47) | ALOX15ALDH1A1ITGB3ITGA2BITGB1 | |
| SCHEMBL1214369 | 0.94 | ALOX15 (0.40) | ALOX15ALDH1A1ITGB3ITGA4PPARG | |
| SCHEMBL1213374 | 0.94 | ALOX15 (0.41) | ALOX15ALDH1A1ITGA4KDM4ESMN1; SMN2 | |
| SCHEMBL1216189 | 0.93 | ALOX15 (0.44) | ALOX15ALDH1A1TRPV1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7829592-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2010-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, PARK7, DDT | ALOX15 513/4885ALDH1A1 636/4885ITGB3 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.